(S)1-(2’-allylphenoxy)-2,3-epoxypropane | 81840-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (S)1-(2’-allylphenoxy)-2,3-epoxypropane
• 英文别名: (S)-2-((2-allylphenoxy)methyl)oxirane；S(+)-1-(2-allylphenoxy)-2,3-epoxypropane；(2S)-2-[(2-allylphenoxy)methyl]oxirane；(2S)-2-[(2-prop-2-enylphenoxy)methyl]oxirane
• CAS: 81840-59-7
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: XENMLDGAMXHYMH-NSHDSACASA-N

物化性质

• 沸点：
  278.8±15.0 °C(Predicted)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)1-(2’-allylphenoxy)-2,3-epoxypropane 在 盐酸 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 (S)-13-amino-1-(2-(prop-2-en-1-yl)phenyl)-1,8,11-trioxa-5-azatridecan-3-ol
  参考文献：
  名称：

  Synthesis and Characterization of High-Affinity 4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene-Labeled Fluorescent Ligands for Human β-Adrenoceptors

  摘要：

  The growing practice of exploiting noninvasive fluorescence-based techniques to study G protein-coupled receptor pharmacology at the single cell and single molecule level demands the availability of high-quality fluorescent ligands. To this end, this study evaluated a new series of red-emitting ligands for the human beta-adrenoceptor family. Upon the basis of the orthosteric ligands propranolol, alprenolol, and pindolol, the synthesized linker-modified congeners were coupled to the commercially available fluorophore BODIPY 630/650-X. This yielded high-affinity beta-adrenoceptor fluorescent ligands for both the propranolol and alprenolol derivatives; however, the pindolol-based products displayed lower affinity. A fluorescent diethylene glycol linked propranolol derivative (18a) had the highest affinity (log K-D of -9.53 and -8.46 as an antagonist of functional beta 2- and beta 1-mediated responses, respectively). Imaging studies with this compound further confirmed that it can be employed to selectively label the human beta 2-adrenoceptor in single living cells, with receptor-associated binding prevented by preincubation with the nonfluorescent beta 2-selective antagonist 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]-butan-2-ol (ICI 118551) (J. Cardiovasc. Pharmacol. 1983, 5,430-437.)

  DOI：

  10.1021/jm2008562
• 作为产物：
  描述：

  1-(2-allyl-phenoxy)-3-chloro-propan-2-ol 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 (S)1-(2’-allylphenoxy)-2,3-epoxypropane
  参考文献：
  名称：

  酶辅助制备对映体纯的β-肾上腺素能阻滞剂III。旋光氯醇衍生物及其转化

  摘要：

  两个对映体系列的光学活性氯代醇衍生物2a-m和3a-m是通过酶水解和由假单胞菌属物种的高度选择性脂肪酶催化的酰基转移反应制备的。。将得到的结构单元进一步转化为高对映体纯度的相应β-受体阻滞剂。

  DOI：

  10.1016/s0957-4166(00)80256-6

文献信息

• Probing the Existence of a Metastable Binding Site at the β₂-Adrenergic Receptor with Homobivalent Bitopic Ligands
  作者：Birgit I. Gaiser、Mia Danielsen、Emil Marcher-Rørsted、Kira Røpke Jørgensen、Tomasz M. Wróbel、Mikael Frykman、Henrik Johansson、Hans Bräuner-Osborne、David E. Gloriam、Jesper Mosolff Mathiesen、Daniel Sejer Pedersen

  DOI：10.1021/acs.jmedchem.9b00595

  日期：2019.9.12

  development of bitopic ligands aimed at targeting the orthosteric binding site (OBS) and a metastable binding site (MBS) within the same receptor unit. Previous molecular dynamics studies on ligand binding to the β2-adrenergic receptor (β2AR) suggested that ligands pause at transient, less-conserved MBSs. We envisioned that MBSs can be regarded as allosteric binding sites and targeted by homobivalent bitopic

  在本文中，我们报道了针对同一受体单元内正构结合位点（OBS）和亚稳结合位点（MBS）的双配位配体的开发。先前对配体与β2-肾上腺素受体（β2AR）结合的分子动力学研究表明，配体在瞬时的，保守性较低的MBSs处暂停。我们设想，MBS可以被视为变构结合位点，并由连接两个相同药效基团的同双价双位配体靶向。基于拮抗剂（S）-普萘洛尔对接至OBS和MBS中来设计此类配体并进行合成。药理学特征显示，与（S）-阿普萘洛尔相比，配体具有相似的效价和亲和力，β2/β1AR选择性略有增加，和/或β2AR的离解速率大大降低。截短的双位配体表明亚稳态药效团的主要贡献是与β2AR的疏水相互作用，而单独的接头降低了正构片段的效力。总而言之，该研究强调了靶向MBS改善配体药理作用的潜力。
• Asymmetric hydrolytic kinetic resolution with recyclable polymeric Co(<scp>iii</scp>)–salen complexes: a practical strategy in the preparation of (S)-metoprolol, (S)-toliprolol and (S)-alprenolol: computational rationale for enantioselectivity
  作者：Tamal Roy、Sunirmal Barik、Manish Kumar、Rukhsana I. Kureshy、Bishwajit Ganguly、Noor-ul H. Khan、Sayed H. R. Abdi、Hari C. Bajaj

  DOI：10.1039/c4cy00594e

  日期：——

  epoxide (up to 46% compared to 50% theoretical yield) along with high enantioselectivity (up to 99%) were obtained in most cases using catalyst 1. Further studies showed that catalyst 1 could retain its catalytic activity for six cycles under the present reaction conditions without any significant loss in activity or enantioselectivity. To show the practical applicability of the above synthesized catalyst

  合成了一系列基于许多非手性和手性连接基的手性聚合Co（III）-salen配合物，并在末端环氧化物的不对称水解动力学拆分中评估了它们的催化性能。明智地研究了该连接基的作用，发现在手性BINOL型聚合物Salen配合物1的情况下，未反应的环氧化物的催化剂反应性和对映选择性的增加，特别是在短和短的情况下。长链脂族环氧化物。在大多数情况下，使用催化剂1可获得良好的分离度，即未反应的环氧化物的收率高（高达50％的理论收率的46％），以及高对映选择性（高达99％）。进一步的研究表明，催化剂在当前的反应条件下，图1所示的催化剂可以保持其催化活性六个循环而没有任何活性或对映选择性的明显损失。为了显示上述合成催化剂的实际适用性，我们使用配合物1以中等收率和高对映选择性合成了一些有效的手性β-阻滞剂。DFT（M06-L / 6-31 + G ** // ONIOM（B3LYP / 6-31G *：STO-3
• Heterocyclic beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020028832A1

  公开（公告）日：2002-03-07

  This invention provides compounds of Formula I having the structure 1 U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构式I的化合物 1 其中U、V、W、X和Y如前文所定义， 或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。
• Aryloxypropanolaminotetralins, a process for their preparation and
  申请人：Elf Sanofi

  公开号：US05254595A1

  公开（公告）日：1993-10-19

  Aryloxypropanolaminotetralins with beta-antagonist activity of the formula ##STR1## wherein R is hydrogen, hydroxy or methoxy and Ar is an optionally substituted aromatic or heteroaromatic group, in optically active or inactive form as well as their acid addition salts are described. A process for their preparation and pharmaceutical compositions containing the compounds of formula (i) or their pharmaceutically acceptable acid addition salts, are also described.

  具有β-阻断活性的芳氧基丙醇胺四氢萘，其通式为##STR1##，其中R为氢、羟基或甲氧基，Ar为可选择性取代的芳香或杂芳香基团，以光学活性或非活性形式及其酸加成盐被描述。它们的制备方法以及含有通式(i)化合物或其药学上可接受的酸加成盐的药物组合物也被描述。
• Jacobsen-type enantioselective hydrolysis of aryl glycidyl ethers.³¹P NMR analysis of the enantiomeric composition of oxiranes
  作者：A. A. Bredikhin、E. I. Strunskaya、V. G. Novikova、N. M. Azancheev、D. R. Sharafutdinova、Z. A. Bredikhina

  DOI：10.1023/b:rucb.0000024851.29744.21

  日期：2004.1

  The enantioselective partial hydrolysis of a number of racemic aryl glycidyl ethers in the presence of chiral Co(salen)-catalyst was studied. The enantiomeric composition of the isolated (R)-aryl glycidyl ethers was analyzed by 31P NMR using optically active substituted 2-chloro-1,3,2-dioxaphospholanes. A synthesis of β-adrenoblocking agents (S)-toliprolol and (S)-moprolol based on the simultaneously

  研究了在手性 Co(salen) 催化剂存在下，许多外消旋芳基缩水甘油醚的对映选择性部分水解。分离的(R)-芳基缩水甘油醚的对映体组成通过31P NMR使用光学活性取代的2-氯-1,3,2-二氧杂环戊烷进行分析。提出了基于同时获得的 (S)-3-芳氧基丙烷-1,2-二醇合成 β-肾上腺素阻滞剂 (S)-toliprolol 和 (S)-moprolol。